Although the association between cisplatin sensitivity and ERCC1 expression level was not as strong in our eight NSCLC cell lines as in previous reports, the present study found that ERCC1 expression had a very clear predictive role with regard to the efficacy of panobinostat and cisplatin combination therapy. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.